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Background:A signiﬁcant proportion of patients admitted for acute decompensated heart failure (ADHF) that un-
dergo volume reduction therapy are discharged with unchanged or increased bodyweight suggesting that the
endpoints for these therapies are not optimally deﬁned. We aimed to identify vectors that can help monitor
changes in intravascular ﬂuid volume, that in turn may more accurately guide volume reduction therapy.
Methods:Data from six different impedance vectors and corresponding changes in intravascular volume derived
from changes in hematocritwere obtained from132 clinical congestion events in 56 unique patients enrolled in a
multisite trial of early detection of clinical congestion events (DEFEAT PE). Mixed effects regressionmodels were
used to determine the relation between changes in impedance derived from six different vectors and changes in
intravascular plasma volume.
Results: Changes in impedancewere negatively associatedwith changes in plasma volume. Two vectors, the right
atrial ring to left ventricular ring and the left ventricular ring to the right ventricular ring, were most closely
associated with changes in intravascular plasma volume.
Conclusion: Impedance vectors derived from a multivector monitoring system reﬂect changes in intravascular
plasma volume. Two of these vectors most closely track changes in plasma volume and may be used to more
accurately guide and optimize volume reduction therapy.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heart failure (HF) is a leading cause ofmorbidity andmortality in the
US and signiﬁcantly contributes to national health care costs [1]. Due to
the progressive and unstable natural history of HF,many patients devel-
op recurrent episodes of acute decompensated heart failure (ADHF)
requiring frequent hospital admissions [2]. The health care costs associ-
ated with heart failure are mainly due to these events and are expected
to increase by 120% by 2030 [1]. ADHF and refractory congestive heart
failure (CHF) are considered the end product of a vicious cycle of, OH 43210-1252, United States.
y).
eliability and freedom from bias
land Ltd. This is an open access articlreduced cardiac output, impaired salt andwater renal excretion and con-
sequent neurohormonal activation. It often results in volume overload,
body water redistribution and concomitant high cardiac ﬁlling pressures
[3]. In the US, approximately 90% of all heart failure related admissions
are due to symptoms of pulmonary congestion and ﬂuid overload that
are in turn associated with HF progression and increased mortality [4].
Estimation of total bodywater and redistribution of extra and intravascu-
lar volumes is crucial for assessment and treatment of these patients and
has been the focus of research and care innovations [5,6].
Although intrathoracic impedance monitoring has been exten-
sively studied as a means for early detection of clinical congestion
events resulting from the above mechanisms, there has been little
attention given to its role in monitoring or guiding volume reduction
therapies.Many implantable deﬁbrillator systems and biventricular
pacing devices have incorporated intrathoracic impedance measure-
ment in their monitoring capabilities [7–10]. Therefore, a large numbere under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Diagram of CRDT impedance vectors. Electrode conﬁgurations used for measuring
impedance: (1) LVr–RVr, (2) LVr–RAr, (3) RVr–can, (4) LVr–can, (5) RAr–can, and
(6) RVc–can. LV: left ventricle, RA: right atrium, RV: right ventricle, c: coil electrode, r: ring
electrode. Modiﬁed from Binkley et al. [15].
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volume reduction therapies. Strategies to effectively use this informa-
tion should be developed.
It has been reported in the literature that as many as 50% of ADHF
admitted patients treatedwith diuretics are dischargedwith unchanged
or increased body weight compared to admission despite clinical
improvement [11]. This suggests that clinical endpoints used to direct
and terminate diuretic therapymight be inappropriate. One explanation
for this observation is that effective volume reduction therapy ideally
targets decreased extravascular volume without signiﬁcant reduction
in intravascular volume that elicits activation of neurohormonal mech-
anisms that promote ﬂuid retention and a net increase in total body
water. Therefore, effective volume monitoring must reﬂect not only
total intrathoracic volume but must isolate the intravascular from the
extravascular ﬂuid compartment [12].
Recently developed volume monitoring algorithms have used the
multiple impedance vectors that can be derived across different leads
of pacing systems in an effort tomore accurately detect volume changes
[13]. It is possible that among these, speciﬁc vectors or their combina-
tions more accurately report changes in plasma volume rather than
extravascular or total intrathoracic ﬂuid volume.
We therefore aimed to examine the relationship between different
impedance vectors to changes in plasma volume and thus identify
vectors that most accurately report changes in the intravascular com-
partment. Identiﬁcation of vectors that speciﬁcally isolate the intravas-
cular volume compartment will contribute to signiﬁcant advances in
the direction of volume reduction therapies and address an important
unmet need in the treatment of acute decompensated heart failure.
2. Methods
2.1. Patient sample
The study sample was derived from participants in the pivotal trial
(DEFEAT PE; ClinicalTrials.gov, NCT00916929) of a multivector algo-
rithm for prevention of clinical volume overload events sponsored by
St. Jude Medical. All subjects had heart failure with standard indications
for either an ICD or CRTD device and were required to have at least one
episode of decompensated congestive heart failurewithin sixmonths of
study enrollment. The participants in this sub-study were those who
were admitted to a hospital for decompensated heart failure events
for whom serial hematocrit data were available along with impedance
vector data encompassing the time period of volume reduction therapy.
Patients who received blood transfusions, had episodes of active bleed-
ing during an admission or who had a history of a lead dislodgment
were excluded from the analysis.
2.2. Estimation of percent plasma volume change
Percent change in plasma volume (ppchange) at any two points
during a hospitalization was determined by using a formula that has
been successfully used in clinical hemodialysis and ultraﬁltration [14].
Percentchangeinplasmavolume ¼ 100= 100−Hctpreð Þð Þ
 100 Hctpre−Hctpostð Þ=Hctpostð Þ:
Where Hctpre is the ﬁrst hematocrit measurement and Hctpost is a
subsequent measure.
For this study, we chose two hematocrit values that were separated
by the greatest time interval during volume reduction therapy.
Positive values of percent plasma volume change represent an
increase in plasma volume from the time when the ﬁrst hematocrit
sample was drawn to the time of the repeated measurement.2.3. Analysis of impedance vectors
The CRTD device measures impedances obtained from six indepen-
dent vectors formed by the following electrode conﬁgurations (Fig. 1):
(1) LVr–RVr, LV ring electrode to RV ring electrode;(2) LVr–RAr, LV
ring electrode to right atrium (RA) ring electrode; (3) RVr–Can, RVring
electrode to device can;(4) LVr–Can, LV ring electrode to device can;
(5) RAr–Can,RA ring electrode to device can; and (6) RVc–Can, RV coil
electrode to device can. Impedance measurements were recorded
every 2 h[15]. The ICD device onlymeasures impedance vectors for con-
ﬁgurations: (3) RVr–Can, RVring electrode to device can, (5) RAr–Can,
RA ring electrode to device can; and (6) RVc-Can, RV coil electrode to
device can.
Impedancedata fromeach vector obtained at times thatmost closely
corresponded to acquisition of the hematocrits were selected for analy-
sis. Therefore impedance measurements corresponding to the ﬁrst and
second of two hematocrit measures were analyzed for each of the six
vectors. If the available impedance data were more than 2 h from a
corresponding hematocrit, the observation was not included in the
analysis. The change in impedance for each vector was calculated by
subtracting the post-hematocrit related impedance (PostImp) from
the pre-hematocrit related impedance (PreImp) values as follows:
Impedancevectordifference : PostImp−PreImp:
Therefore, positive values of impedance difference represent an
increase in impedance overtime, while negative values represent a
decrease of impedance.
2.4. Statistical analysis
Changes in impedance and percent plasma volume were represented
by themean and standard deviation. The association between changes in
impedance and plasma volume was analyzed using mixed linear models
to account for inter-subject variability inmeasures and the different num-
ber of measurements made on each participant. Sequential models were
constructed consisting of themixed effects model with random intercept
(deﬁned by the patient identiﬁcation number) and the mixed effecfs
model with both random intercept and coefﬁcient relating change in
impedance and change in plasma volume. Models were constructed for
each of the six impedance vectors. The likelihood ratio test was used to
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improved the model compared to the previous step. Statistical signiﬁ-
cance was set at the 0.05 level for all analyses.
The Akaike information criterion (AIC) for non-nested models was
used to determine which of the regression models showed the best ﬁt
between changes in impedancemeasures and change in percent plasma
volume. All analyses were performed using Stata 13®.3. Results
Clinical characteristics of the study participants are shown in Table 1.
Hematocrits and corresponding impedance data were available for
136 congestion events on 59 unique admitted patients. Single observa-
tions from four of these patients were eliminated owing to requirement
for blood transfusions (n: 3) or pacemaker lead fracture (n: 1). Accord-
ingly, we analyzed data from 132 observations obtained on 56 unique
patients. Twenty four patients had data available for only one admis-
sion, while the remainder had multiple admissions ranging from 2 to
11. Fifty seven percent of the patients (n: 32) had a CRDT device and
forty-three percent had an ICD device only. Of all observations, there
was an estimated 65% incidence of increase in plasma volume during
the treatment period. The distribution of the number of hospital days
over which hematocrit and impedance measures were obtained wasTable 1
Clinical characteristics of study participants.
Demographic variable Number of patients
(N = 132)
Age (years)
Mean ± SD 66 ± 14
Range (26, 88)
Gender, n (%)
Female 27 (20.5%)
Male 105 (79.5%)
Race/ethnicity, n (%)
Black or African American 61 (46.2%)
Hispanic or Latino 10 (7.6%)
White 61 (46.2%)
NYHA class, n (%)
I 9 (6.8%)
II 53 (40.2%)
III 70 (53.0%)
LV ejection fraction (%)
Mean ± SD 25 ± 8
Range (10, 50)
Cardiomyopathy classiﬁcation
Ischemic, n (%) 77 (58.3%)
Non-ischemic, n (%) 55 (41.7%)
Cardiovascular history
Coronary artery disease 89 (67.4%)
Myocardial infarction 72 (54.5%)
CABG 53 (40.2%)
PTCA 34 (25.8%)
Unstable angina 40 (30.3%)
Arrhythmia history
Ventricular 71 (53.8%)
Non-ventricular 69 (52.3%)
Pulmonary medical conditions
Asthma 12 (9.1%)
COPD 42 (31.8%)
Pulmonary ﬁbrosis 2 (1.5%)
Pulmonary hypertension 39 (29.5%)
Sarcoidosis 6 (4.5%)
Sleep apnea 15 (11.4%)
Partial left lower lobe resection 1 (0.8%)
Pulmonary embolism 3 (2.3%)
Cardiac medications at enrollment
ACE inhibitors 79 (59.8%)
Angiotensin receptor blockers (ARB) 17 (12.9%)
Beta-blockers 115 (87.1%)
Diuretics 124 (93.9%)positively skewed.Themedian number of days was 4with an interquar-
tile range of 2 to 7 days.There was no signiﬁcant difference (p=0.7) in
the number of hospital days for those with no change or a decrease in
plasma volume (4 days; interquartile range 2 to 6 days)and those
with an increase in plasma volume (4 days; interquartile range 2 to
7 days).
The mean and standard deviations for the change in plasma volume
and corresponding changes in the six impedance vectors for the entire
group are shown in Table 2. The average changes in impedance for the
six vectors in the group with an increase in estimated plasma volume
and that with a maintained or decrease are shown on the right hand
of Table 2. There was a decrease in mean impedance change for ﬁve of
the six vectors in congestion events with an increase in percent plasma
volume and an increase in themean impedance change for all vectors in
the group with a decrease in plasma volume. Therefore, other than the
LV ring to can vector in the group with an increase in plasma volume,
all impedance vectors exhibited the changes expected based on the
known relation between electrical impedance and ﬂuid ﬁlled media.3.1. Mixed effects models
The log likelihood and the overall model signiﬁcance of the random
intercept and the random intercept plus random slope models for each
of the six vectors are shown in Table 3.
Five of the six impedance models showed a signiﬁcant relationship
with percent change in plasma volume using a ﬁxed effects only
model. Although the LV ring to can vector did not show a signiﬁcant
relation with change in plasma volume in a ﬁxed effect model, it and
the remaining ﬁve vectors showed a progressive increase in model
signiﬁcance with addition of random intercept and random slope
models. For each of the six vectors, hierarchical likelihood ratio tests
showed an increase inmodel signiﬁcancewith the addition of a random
slope to the random interceptmodel. In all vectors, the ﬁxed effect coef-
ﬁcient became increasingly negative with the addition of the random
slope. Therefore, when correcting for inter-subject variability, the direct
inverse relation between change in impedance and change in percent
plasma volume is strengthened for each of the vectors.
The impedance vector with the best model ﬁt to the percent change
in plasma volumewas identiﬁed using the Akaike information criterion
(AIC). This statistic is useful in comparingmodels that are not hierarchi-
cal, such as the different regressionmodels for the different impedances,
and is based on model log likelihood with a penalty for number of
variables contained in the model. Because the models with the random
intercept and slope were the most signiﬁcant for each vector, theseTable 2
Descriptive summary of percent change in plasma volume and impedance difference for
all vectors.
Variables Entire group N0 ppchange
(n:86)
≤0 ppchange
(n:46)
Mean SD Mean SD Mean SD
Estimated percent plasma change
Plasma change (%) 7.13 16.12 15.73 12.69 −8.93 6.83
Impedance vector differences
LVr to RVra (Ω) 2.92 31.40 −0.68 32.13 11.63 29.10
RAr to LVra (Ω) −1.23 32.05 −5.55 32.48 9.34 29.75
RVr to can (Ω) 1.70 15.28 −2.50 13.46 9.51 15.71
LVr to cana (Ω) 4.91 29.86 4.68 33.42 5.91 20.37
RAr to can (Ω) −0.90 19.56 −6.16 17.94 8.66 19.23
RVc to can (Ω) 1.35 6.40 −0.12 5.28 4.12 7.45
Estimated percent change in plasma volume (ppchange) = (100 / (100 − Hctpre)) ∗
(100(Hctpre− Hctpost) / Hctpost).
Impedance vector differences were calculated by the subtraction of the post-value–
pre-value.
a These impedance vectors do not exist for ICD devices, and thus were not available for
all observations.
Table 3
Sequential random effects models for each impedance vector and their respective Log
likelihoods (Log LH).
I. Vector Random intercept models Random intercept + slope
models
LR testa
Log LH p-value Coef Log LH p-value Coef p-value
LVr to RVr −339.5 0.0023 −0.168 −335.9 0.0034 −0.253 0.0246
RAr to LVr −337.9 0.0002 −0.194 −332.0 0.0013 −0.299 0.0085
RVr to can −533.0 b0.0001 −0.488 −523.7 b0.0001 −0.602 b0.0001
LVr to can −342.4 0.0662 −0.108 −337.3 0.0336 −0.227 0.0132
RAr to can −429.2 b0.0001 −0.469 −419.8 b0.0001 −0.586 b0.0001
RVc to can −5435.3 b0.0001 −1.05 −530.7 b0.0001 −1.08 0.0132
Coef: ﬁxed effects impedance vector slope coefﬁcient.
Random intercept model: ﬁxed effects + random intercept (patient ID).
Random intercept + slope model: ﬁxed effects + random intercept + random slope.
a LR test: likelihood ratio test, compares random slope model with the random intercept
model.
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shown in Table 4. The smaller the AIC, the better the model ﬁt.
Based on theAIC, the vector deﬁned by theRAr to LVr had the best ﬁt
with change in percent plasma volume.4. Discussion
This study provides foundation data for the use of intrathoracic
impedance monitoring as a novel and effective means to guide volume
reduction therapy. Given the absence of proven clinical endpoints for
the administration of volume reduction therapies, the ﬁndings address a
signiﬁcant unmet need in the clinical management of acute decompen-
sated heart failure.
All six of the intrathoracic impedance vectors showed the expected
inverse relationship between change in impedance and percent change
in plasma volume in the mixed effects models. The inverse relationship
between impedance vectors and percent change in plasma volume is
consistent with the known increase in electrical conductivity through
ﬂuid ﬁlled media. To the authors' knowledge, this is the ﬁrst in vivo
demonstration in humans that intrathoracic impedance indeed follows
the expected inverse relation. Furthermore, this study identiﬁes imped-
ance vectors that are most closely associated with changes in plasma
volume and thereforemay be themost informative vectors formonitor-
ing volume reduction therapy.
The ability to speciﬁcally isolate changes in intravascular volume is
of importance when considering the pathophysiology and treatment
of congestion states [6]. It has been noted that the goal in congestion
therapy is reduction of interstitial ﬂuid volume with preservation of
intravascular volume [3,4,6,12]. When treatment for congestion states
results in marked reduction of intravascular ﬂuid volume, an iatrogenic
cardiorenal syndrome can result with activation of the renin–angioten-
sin axis and other systems that promote ﬂuid retention rather than
volume loss. Indeed, over half of the instances of volume reduction
therapy in our studywere accompanied by an estimated increase rather
than decrease in percent plasma volume. This is consistentwithﬁndings
in the Acute Decompensated Heart Failure National Registry (ADHERE)Table 4
Akaike information criterion (AIC) for all signiﬁcant random coefﬁcient
models.
Impedance vector models AIC
RAr to LVr 677.3251
LVr to RVr 683.36
LVr to can 686.77
RAr to can 851.61
RVr to can 1059.554
RVc to can 1073.491in which 50% of patients were discharged from the hospital with either
no change or an increase in weight following volume reduction therapy
[4].
Two vectors, RA ring to LV ring and RV ring to LV ring, were found to
be most closely associated with percent change in plasma volume. It is
not surprising that these two vectorswould isolate changes in the intra-
vascular volume compartment based on their spatial and anatomic ori-
entation (Fig. 1). These vectors traverse cardiac chambers and exclude
interstitialﬂuid compartments. In contrast, vectors such as those includ-
ing the pacer can will encompass the interstitial ﬂuid compartments in
the lungs and chestwall aswell as theﬂuid volume contained in the car-
diac chambers. Indeed, the LV ring to can vector did not show a signiﬁ-
cant correlation with change in plasma volume in the ﬁxed effect and
random intercepts models.In general, the vectors including the pacer
can showed the weakest association with change in plasma volume in
the random effects models. This weaker association is likely due to the
inﬂuence of these vectors by multiple ﬂuid compartments beyond the
intravascular compartment alone.
The random slope models were superior to the random intercept
only models since they account for an additional component of the
expected intersubject variability in anatomy and orientation of pace-
maker leads. That the random slope for the relationship between chang-
es in plasma volume and impedance added signiﬁcantly to the model
indicates that the regression lines relating thesemeasures for the differ-
ent subjects are not parallel. It would in fact be surprising if the regres-
sion lines were parallel considering anatomic variation and orientation
of pacemaker leads between subjects. Accounting for the randomeffects
due to intersubject variability resulted in an even greater negative ﬁxed
effect coefﬁcient, which represents the group mean of the relation
between change in plasma volume and impedance. This further supports
the inverse relation between changes in plasma volume and impedance.
4.1. Implications for treatment of congestion states
The capacity to isolate intravascular from extravascular volume
compartments provides a unique opportunity to more effectively treat
clinical congestion states. As noted above, overly aggressive congestion
therapy can produce decreases in intravascular volume that induce a
cardio-renal syndrome. As a result, total body water will increase rather
than decrease. Optimalmanagement of clinical congestion states requires
an understanding of changes in intravascular volume and the delicate
balance between excess intravascular volume and deleterious volume
reductions in this compartment. Studies of ultraﬁltration therapy have
indicated that volume reduction therapy is ideally monitored by the
capillary reﬁll rate [12]. This measurement is determined by the net
change in intravascular volume resulting from movement of extravascu-
larﬂuid to the intravascular compartment and eliminationof excess intra-
vascular ﬂuid by renal excretion. Ideally, this rate shouldmaintain the net
change in intravascular volume at zero. If this rate results in a decrease in
intravascular volume, activation of neurohormonalmechanisms that pro-
mote increases in total body water may result. In fact, the failure to
accurately monitor changes in intravascular volume may account for the
maintenance or increase in weight noted in the ADHERE registry and
the increases in intravascular volume noted in a subset of patients in
the current study. The use of impedance vectors that most closely reﬂect
changes in intravascular volume can prevent excessive volume reduction
therapy. A small preliminary study has investigated the use of impedance
monitoring to ascertain readiness for hospital discharge [16]. However,
that study did not select an impedance vector that most accurately
reﬂected changes in plasma volume for therapeutic monitoring.
Therefore, strategies to monitor volume reduction therapy for acute
decompensated heart failure could consist of tracking impedance
changes reported by the vectors that most accurately reﬂect changes
in intravascular plasma volume. A persistent increase in impedance in
these vectors, indicating a decreased intravascular volume,would signal
the termination of volume reduction therapies.This would prevent
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mechanisms that in fact promote volume retention. Conversely, persis-
tent decreases in impedance in vectors most closely correlated with
changes in plasma volume can indicate signiﬁcant volume shifts not
reﬂected by changes in body weight that may require initiation or
resumption of volume reduction therapies [6]. Although not speciﬁcally
tested in the current study, differential changes in impedance measured
by those vectors closely correlated with intravascular volume alone and
those that are reﬂective of total intrathoracic volume could provide
important information regarding the relative changes in intravascular
and extravascular volume compartments and further guide the course
of volume reduction therapy.
4.2. Study limitations
These datawere obtained from a subset of patients in a larger pivotal
trial. Only patients who had a congestion event were included since
hemoglobin and hematocrit data were available only in those subjects.
Although it is plausible that the same relationships between change in
impedance and intravascular volume would pertain in other study
participants, this cannot be determined with certainty in the current
analysis.
Changes in hematocrit constitute only an indirect measure of plasma
volume. However, this measure has been used in numerous prior studies.
We speciﬁcally excluded patients with acute bleeding or those who
obtained blood transfusions that would result in rapid changes in hemat-
ocrit. This increases conﬁdence that the hematocrit changes measured in
the current study were indeed due to changes in intravascular volume.
The strongest correlations with changes in plasma volume were
obtained with impedance vectors available in biventricular pacing
systems. Therefore, the ﬁndings of this studymay not be readily applied
to those with non-CRT systems. A relatively strong relation between
change in impedance and plasma volume was observed with the RAr
to can vector suggesting that intravascular volume monitoring may
still be possible in patients with devices having atrio-ventricular pacing
as well as deﬁbrillating capabilities. However, it is estimated that over
500,000 patients in the US have biventricular pacing devices (personal
communication Hans Schafer, St. Jude Medical). Accordingly a signiﬁ-
cant proportion of patients with heart failure could beneﬁt from this
strategy for guiding volume reduction therapies.
4.3. Conclusions
It has been noted thatmonitoring of bodyweightmay bemisleading
in either the detection of congestion or monitoring response to therapy
since congestionmay be due to volume compartment shifts rather than
changes in absolute body water. Accordingly, the use of intrathoracic
impedance vectors that accurately reﬂect changes in intravascular
volume can signiﬁcantly advance the guidance of volume reduction
therapies with improved outcomes including the need for early hospital
readmission. The current ﬁndings provide the foundation for future
studies investigating the use of impedance vectors that most closely
reﬂect changes in intravascular volume to accurately guide volume
reduction therapy and advance themanagement of acute decompensated
heart failure.
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